The recurrence rate of colorectal liver metastases (CRLM) patients treated with curative
intent is above 50%. Standard of care surveillance includes intensive computed …

PURPOSE Prognostic tools to estimate the risk of relapse for patients with liver-limited
metastatic colorectal cancer (LL-mCRC) undergoing resection with curative intent are …

Purpose Nearly 50% of patients recur within two years after curatively intended resection of
colorectal cancer liver metastasis (CRLM). The optimal surveillance strategy is unknown due …

Background In patients with resectable colorectal liver metastases (CRLM), the role of pre-
and postoperative systemic therapy continues to be debated. Previous studies have shown …

Background Recurrence rates after resection of colorectal cancer liver metastases (CRLM)
are high and correlate with worse survival. Postoperative circulating tumour DNA (ctDNA) is …

e15131 Background: In pts with metastatic colorectal cancer (mCRC), the resection of
isolated CLM is potentially curative. Previous studies have shown that ctDNA can be …

Circulating tumour DNA (ctDNA) is a potential biomarker that could contribute to more
judicious patient selection for personalised treatment. This review and meta-analysis gives …

Background The optimal perioperative management of patients who undergo hepatectomy
for resectable colorectal liver metastases (CRLM) remains unclear due to the lack of reliable …

Background The surgical resection of colorectal cancer with liver metastases (CLM) has
proven to be the most important modality for long-term survival, while effective biomarkers …

Studies in multiple solid tumor types have demonstrated the prognostic significance of
ctDNA analysis after curative intent surgery. A combined analysis of data across completed …